Evidence map›Paper›PMID 42609618›Full record

ReviewFrontiers in immunology2026

TET2: a critical regulatory hub with broad therapeutic implications across human diseases.

Jingyi Tang, Ruoxian Wang, Li Long, Wencheng Ma, Xiaofan Han, Hongxue Fu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingyi Tang *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Ruoxian Wang *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Li Long *School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Wencheng MaSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
Xiaofan HanMolecular Biology Laboratory, Chongqing Medical and Pharmaceutical College, Chongqing, China.
Hongxue FuDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ten-Eleven Translocation 2 (TET2) is a pivotal α-ketoglutarate and Fe

Indexed as

DNA-Binding ProteinsProto-Oncogene Proteins5-MethylcytosineAnimalsCardiovascular DiseasesDioxygenasesDNA MethylationEpigenesis, GeneticHumansInflammationMetabolic DiseasesNeoplasms5-MethylcytosineDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humancancerDNA demethylationepigenetic regulationinflammationmetabolic diseasesTET2

Identifiers

PMID42609618
PMCPMC13479435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.